FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

							()				<u> </u>			,						
Name and Address of Reporting Person* Cannon Gillian						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Calliloi	ı Gillidi				1							_ [) X	Directo	r		10% Ov	mer	
(Last) (First) (Middle) C/O CORCEPT THERAPEUTICS INCORPORATED					3. Date of Earliest Transaction (Month/Day/Year) 05/26/2021									_	Officer below)	(give title		Other (s below)	pecify	
149 COMMONWEALTH DRIVE					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)							
(Stroot)														<u> </u>	X Form filed by One Reporting Person					
(Street) MENLO PARK CA 94025															Form filed by More than One Reporting Person					
(City)	ı	(State)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.				4 and Securiti Benefic Owned		es Fo ially (D) Following (I)	Form (D) or	orm: Direct 0) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	nount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execution Date, if any		4. Transaction Code (Instr. 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)			and 7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)			3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				c	ode	v	(A)	(D)	Date Exercisable		expiration Date	Title	or Nu of	ount mber ares						
Stock Option (Right to Buy)	\$21.45	05/26/2021			A		20,000		(1)	0	5/25/2031	Common Stock	20	,000	\$0.00	20,000)	D		

Explanation of Responses:

1. Exercisable ratably in equal installments on each monthly anniversary of May 26, 2021 over a one-year period.

Remarks:

/s/ Joseph Douglas Lyon, Attorney-in-Fact for Gillian M. 05/28/2021 Cannon

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.